Ocumension (Hong Kong) Limited
Quick facts
Phase 3 pipeline
- OT-101 Ophthalmic Solution · Ophthalmology
OT-101 is a small-molecule inhibitor of the Wnt/β-catenin signaling pathway designed to reduce corneal neovascularization and inflammation in the eye.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: